Publication:
Nutritional approaches in the risk reduction and management of Alzheimer's disease

dc.contributor.authorMi, Weiqian
dc.contributor.authorvan Wijk, Nick
dc.contributor.authorSijben, John W. C.
dc.contributor.authorKamphuis, Patrick J. G. H.
dc.contributor.buuauthorCansev, Mehmet
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentFarmakoloji Ana Bilim Dalı
dc.contributor.researcheridM-9071-2019
dc.contributor.scopusid8872816100
dc.date.accessioned2022-10-04T06:52:25Z
dc.date.available2022-10-04T06:52:25Z
dc.date.issued2013-09
dc.description.abstractAlzheimer's disease (AD) is a heterogeneous and devastating neurodegenerative disease with increasing socioeconomic burden for society. In the past 30 y, notwithstanding advances in the understanding of the pathogenesis of the disease and consequent development of therapeutic approaches to novel pathogenic targets, no cure has so far emerged. This contribution focuses on recent nutritional approaches in the risk reduction and management of AD with emphasis on factors providing a rationale for nutritional approaches in AD, including compromised nutritional status, altered nutrient uptake and metabolism, and nutrient requirements for synapse formation. Collectively these factors are believed to result in specific nutritional requirement in AD. The chapter also emphasizes investigated nutritional interventions in patients with AD, including studies with single nutrients and with the specific nutrient combination Fortasyn Connect and discusses the current shift of paradigm to intervene in earlier stages of AD, which offers opportunities for investigating nutritional strategies to reduce the risk for disease progression. Fortasyn Connect was designed to enhance synapse formation and function in AD by addressing the putative specific nutritional requirements and contains docosahexaenoic acid, eicosapentaenoic acid, uridine-5'-mono-phosphate, choline, phospholipids, antioxidants, and B vitamins. Two randomized controlled trials (RCTs) with the medical food Souvenaid, containing Fortasyn Connect, showed that this intervention improved memory performance in mild, drug-naive patients with AD. Electroencephalography outcome in one of these clinical studies suggests that Souvenaid has an effect on brain functional connectivity, which is a derivative of changed synaptic activity. Thus, these studies suggest that nutritional requirements in AD can be successfully addressed and result in improvements in behavioral and neuro-physiological alterations that are characteristic to AD. The recent advance of methodologies and techniques for early diagnosis of AD facilitates the investigation of strategies to reduce the risk for AD progression in the earliest stages of the disease. Nutrition-based approaches deserve further investigation as an integral part of such strategies due to their low risk for side effects and their potential to affect pathological processes of very early AD.
dc.description.sponsorshipDanone Nutricia
dc.identifier.citationMi, W. Q. vd. (2013). "Nutritional approaches in the risk reduction and management of Alzheimer's disease". Nutrition, 29(9), 1080-1089.
dc.identifier.endpage1089
dc.identifier.issn0899-9007
dc.identifier.issn1873-1244
dc.identifier.issue9
dc.identifier.pubmed23756280
dc.identifier.scopus2-s2.0-84881376185
dc.identifier.startpage1080
dc.identifier.urihttps://doi.org/10.1016/j.nut.2013.01.024
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/23756280/
dc.identifier.urihttp://hdl.handle.net/11452/28954
dc.identifier.volume29
dc.identifier.wos000323235500002
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherElsevier
dc.relation.collaborationYurt dışı
dc.relation.journalNutrition
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectNutrition & dietetics
dc.subjectNutritional intervention
dc.subjectSynapse formation
dc.subjectSynapse function
dc.subjectFortasyn connect
dc.subjectSouvenaid
dc.subjectMild cognitive impairment
dc.subjectLong-chain omega-3-fatty-acids
dc.subjectPolyunsaturated fatty-acid
dc.subjectDocosahexaenoic acid
dc.subjectFolic-acid
dc.subjectDouble-blind
dc.subjectVitamin-e
dc.subjectMediterranean diet
dc.subjectNeurite outgrowth
dc.subjectSynaptic proteins
dc.subject.emtreeAlpha tocopherol
dc.subject.emtreeAntioxidant
dc.subject.emtreeCholine
dc.subject.emtreeCholinesterase inhibitor
dc.subject.emtreeColecalciferol
dc.subject.emtreeCreatine
dc.subject.emtreeCyanocobalamin
dc.subject.emtreeDocosahexaenoic acid
dc.subject.emtreeFatty acid
dc.subject.emtreeFolic acid
dc.subject.emtreeHomocysteine
dc.subject.emtreeIcosapentaenoic acid
dc.subject.emtreeN methyl dextro aspartic acid receptor stimulating agent
dc.subject.emtreePhospholipid
dc.subject.emtreePomegranate extract
dc.subject.emtreeSecoisolariciresinol
dc.subject.emtreeSelenium
dc.subject.emtreeTrace element
dc.subject.emtreeUridine phosphate
dc.subject.emtreeVitamin B group
dc.subject.emtreeVitamin D
dc.subject.emtreeAlzheimer disease
dc.subject.emtreeBrain atrophy
dc.subject.emtreeCaloric restriction
dc.subject.emtreeDiet supplementation
dc.subject.emtreeDiet therapy
dc.subject.emtreeDisease severity
dc.subject.emtreeEarly diagnosis
dc.subject.emtreeElectroencephalography
dc.subject.emtreeHuman
dc.subject.emtreeLifestyle modification
dc.subject.emtreeMediterranean diet
dc.subject.emtreeMental performance
dc.subject.emtreeMild cognitive impairment
dc.subject.emtreeNonhuman
dc.subject.emtreeNutritional requirement
dc.subject.emtreePriority journal
dc.subject.emtreeProdromal symptom
dc.subject.emtreeProtein calorie malnutrition
dc.subject.emtreeReview
dc.subject.emtreeRisk reduction
dc.subject.emtreeSynaptogenesis
dc.subject.scopusDocosahexaenoic Acids; Alzheimer Disease; Fish Oils
dc.subject.wosNutrition & dietetics
dc.titleNutritional approaches in the risk reduction and management of Alzheimer's disease
dc.typeReview
dc.wos.quartileQ2
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Farmakoloji Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: